Cell-in-a-Box is the basis for novel breakthrough cell therapy products designed to treat cancer with minimal side-effects
Cell-in-a-Box containing human cells engineered to activate an anti-cancer prodrug are administered to the patient through a catheter system and deposited in the capillaries leading to the pancreatic tumour. Low dose anti-cancer prodrug (ifosfamide) is given intravenously. The engineered human cells inside Cell-in-a-Box activate the anti-cancer drug which then kills the tumour cells with only minimal side-effects for the patient
Cell-in-a-Box containing human cells engineered to activate an anti-cancer prodrug are administered to the patient through a catheter system and deposited in the capillaries leading to the pancreatic tumour. Low dose anti-cancer prodrug (ifosfamide) is given intravenously. The engineered human cells inside Cell-in-a-Box activate the anti-cancer drug which then kills the tumour cells with only minimal side-effects for the patient

Cancer

Chemotherapeutic agents have a long history of use in the clinic for a variety of cancer. However, the major drawback to their use are the side effects from generally toxicity in the body due to the need for activation in the liver. These side effects limit the dosing of the chemotherapy. We have developed Cell-in-a-Box™, as a means to a create a novel, tumor local site of chemotherapeutic activation. This allows lower doses of chemotherapeutic to be given with enhanced, improved and targeted anti-tumor activity but importantly without the side effects of classical chemotherapy. Safety and efficacy has been demonstrated and published in clinical trials to treat pancreatic cancer. These trials showed a 2 time better median survival of patients. Later stage clinical trials with additional treatments included are now planned and will be performed by our partner, PharmaCyte Biotech. A similar approach has been shown to work in dogs with spontaneously occurring mammary (breast) cancer. This kind of strategy can be used to treat almost all kind of cancer. Moreover, other cancer therapy molecules such as monoclonal antibodies, cell growth inhibitors, anti-angiogenic factors etc can be produced from Cell-in-a-Box™ encapsulated cells.

Advantages of encapsulated cell mediated low dose chemotherapy include:

  • Less or no side effects of treatment
  • More effective anti-tumor effect due to targeted and localised treatment
  • Allows combination chemotherapy regimes
Cell-in-a-Box